Why Choose Us for Pulmonary Hypertension Care?
Evaluating and treating pulmonary hypertension (PH) can be very difficult. Our pulmonary hypertension team at the University of Chicago is considered one of the most knowledgeable in the world.
Making Research a Priority
Our treatment team, in collaboration with our internationally known oncology drug development group, includes some of the first pioneers in PH research. These doctors and nurses are actively involved in studies to better understand the many causes of this cardio-pulmonary disease, so patients benefit from scientific advances when and where they happen.
Our pulmonary hypertension researchers are also aggressively exploring a wide spectrum of treatments to reverse the disease, stabilize patients with advanced disease, and improve quality of life. In addition, the team is developing an extensive biobank of blood specimens that will allow them to determine the specific genes and mechanisms causing PH in a given patient and biomarkers for disease progression to be used in both clinical and research practice.
The State’s Largest Heart Failure Program
The University of Chicago Medicine is home to the largest--and one of the most respected--heart failure programs in Illinois. Each year, we provide comprehensive care to hundreds of heart failure patients and help them learn how to manage their symptoms so they can live the fullest lives possible. This expertise in heart failure complements the depth of knowledge our experts have with PH, making this a uniquely balanced program for our patients.
A Talented Transplant Team
The University of Chicago Medicine is home to some of the most skilled heart and lung surgeons in the world. Each year, we perform about 30 heart transplants. Our heart transplant program is one of the largest in the Midwest. In addition, we also have one of the most experienced lung transplantation programs for patients with refractory and end stage pulmonary vascular diseases.
- Why Choose Us?